To date, there are almost 47 million people affected by the Alzheimer’s disease, in the world. It could affect four times more people in 2050. The Alzheimer’s disease is caused by the action of two toxins: Amyloid and Tau, combined with oxidative stress, and lead to the degeneration of the cells. During more than 20 years, the research has focused either on one or the other of these toxins.
AlzProtect was created by the professors André Delacourte and Patricia Melnyk. Pr. André Delacourte is one of the few doctors who dissected, post-mortem, about a thousand human brains affected, or not, by the Alzheimer’s disease. Until now, the research was isolating the toxins. AlzProtect considered a more global approach. The Amyloid and Tau toxins, annihilate the autophagy system of the cells, this system enable the cells to regenerate. AlzProtect’s core product: AZP2006, is the first molecule that restore the cleaning process of the neurons. AZP2006 is a powerful product with an almost ideal profile when it comes to tolerance, bioavailability, production, conservation and administration. The research on neurodegenerative diseases is long. In order to obtain funds and faster results, AlzProtect has started its research on the progressive supra-nuclear palsy (PSP), an orphan disease. In February 2015, the company obtained, from the European Medicines Agency, the “orphan drug” status for AZP2006. This status offers reductions in administrative expenses, assistance from the EMA in the elaboration of clinical studies’ protocols, a potentially accelerated clinical development and the possibility of being eligible to some subventions. It is an intra-neuronal, non-synaptic drug and it will contribute to the containment, through the healing of the neurons which spread the damage to their neighbors, and through the restoration of the neighbor neurons’ ability to contain it. Nevertheless, it intends to stop the evolution of the damage. Indeed, AlzProtect thinks that AZP2006 is capable of stopping the evolution of Alzheimer’s disease, but the company does not hope to stop it in the strict meaning of the term. The company hopes to prevent it, delay it or slow it down.
In 2014, there was 6,800 phase II and III clinical trials for the cancer against 60 for the Alzheimer’s disease. Yet, every year, the Alzheimer’s disease increase rapidly: we enumerate 225,000 new cases every year in France and we estimate that there will be, in 2020, 1.3M of people affected by the disease in France. This neurodegenerative disease sees its epidemiology double every 20 years in developed countries. The worldwide market will affect 81M people in 2040. When it comes to R&D and the number of patients and deaths, the competition is 40 times less intense with the Alzheimer’s diseases than the cancer. The remuneration of risk will be higher in the neurodegenerative field than in the cancer field in case of a success.
AlzProtect stands out from the competition thanks to : the exceptional bioavailability of its core product (penetration in the brain) its perfect tolerance during human clinical trials of phase 1 on healthy subjects, the absence of additional production, conservation and administration risk, through the intra-neuronal nature (by opposition to synaptic) of its mecanism of action, its powerful simultaneous efficiency on the three major troubles of Alzheimer's diseases, the Abeta toxicity, the degenerative neurofibrillary tangles Tau and the oxidative stress of the neurons, spectacular nature of mice's memory behavioural conservation tests The product stands out by its vocation to a mass medication, opposed to personalized medicine trends, with a reasonable product for itself or a similar product, and a sustainable long-term economic model.